Welcome to the Schizophrenia Resource Centre

Welcome, this website is intended for healthcare professionals in EMEA with an interest in the treatment of schizophrenia. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Prof. Wolfgang Fleischhacker speaks at SIRS May 2014, about the ethics of placebo in clinical trials

Prof.+Wolfgang+Fleischhacker+preview-HD

Prof. Fleischhacker, Director Department of Psychiatry and Psychotherapy, Medical University Innsbruck, Austria, explains his views on the use of placebo in clinical trials. He explains that as a clinician he's always been uncomfortable with the use of placebo in clinical trial, but as a clinical researcher and psychopharmacologist he acknowledges that there are some studies in which they are absolutely necessary when there is no alternative. He suggests restricting the use of placebo controls and goes on to suggest alternative study designs.

Suggestions for further reading:

Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?
Robin Emsley and Wolfgang W. Fleischhacker
Schizophrenia Research, 2-3, 150, pages 427 - 433

See more content on: Ethics, Trial design, Relapse, Refractoriness